Genescà, EulàliaMorgades, MireiaGonzález-Gil, CeliaFuster-Tormo, FranciscoHaferlach, ClaudiaMeggendorfer, ManjaMontesinos, PauBarba, PereGil, CristinaColl, RosaMoreno, María-JoséMartínez-Carballeira, DanielGarcía-Cadenas, IreneVives, SusanaRibera, JordiGonzález-Campos, JoséDíaz-Beya, MarinaMercadal, SantiagoArtola, María-TeresaCladera, AntoniaTormo, MarBermúdez, AranchaVall-Llovera, FerranMartínez-Sánchez, PilarAmigo, María-LuzMonsalvo, SilviaNovo, AndrésCervera, MartaGarcía-Guiñon, AntonioCiudad, JuanaCervera, JoséHernández-Rivas, Jesús-MaríaGranada, IsabelHaferlach, TorstenOrfao, AlbertoSolé, FrancescRibera, Josep-Maria2023-02-092023-02-092021-06-08http://hdl.handle.net/10668/18008The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of ≥3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with ≥3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corresponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying karyotypes with ≥3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), independently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Additional molecular analyses of patients carrying ≥3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel targeted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Adult T-ALLCytogeneticsNGSPrognosisTherapyAdolescentAdultChromosome AberrationsFemaleHumansKaryotypeMaleMiddle AgedNeoplasm, ResidualPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPrognosisYoung Adultresearch article34139642open access10.1016/j.leukres.2021.1066121873-5835https://doi.org/10.1016/j.leukres.2021.106612